another Good income. President XXXX quarter and growth afternoon. and to Sandgaard, call. our Thomas first Welcome name My CEO quarter of announce I'm of positive is revenue net Zynex. earnings to excited
with positive the first straight for per our first history of of an $X revenue million, same of revenue first share last was year. compared million XX% XXXX. EBITDA net highest the was XX% of increase diluted in company. quarter quarter increased $X.XX quarter quarterly quarter to Our the Adjusted quarter the was also income. XXth It the income and to compared the $XX.X It fully
we in and expand continue our progress the to orders grew investment strong across continues the We quarter as force see our for to The expanding sales we U.S. footprint in products. our geographic XXX% first reimbursement year-over-year
subsequent expect growth sales and from demand aggressively of strong a the these periods. new the products. sign is in result reps growth every our the order continued future a is for and orders adding revenue growth to order Order steep sales to we This force see month growth momentum of
the an device we the it, over prescription, decided continue health patients As relief. revenue related typically or device. needing as years our well the or insurance device as supplies and a uses if order length is time may reaches company the longer recognized you to by call after patient the the order of our for no continued the already, is know patient months as use The many pain primarily of of point
In force sales aggressive sustained QX, growth. we our
During the sales continued to filling over reps. across April so up first all far sales aggressive of XX We've adding November our than QX as hired XX we direct territories hiring in goal we year. this reps reach quarter, more new XXX U.S. by in our push
XXX sales expect QX. We the reps end about to just of have by
the growing in as of quarter faster XXXX. is first XX% Revenue than XXXX over not grew we revenue
XXXX result between This and several having was XXXX obviously quarters well growth quarter XXX% is first a for grown XX%. Our over prior. of year-over-year orders
our by model of the used like them for earlier. temporary in now. was monthly patients XX% as tip is in supplies periods derived from helpful use is our Our orders received billing they're slowdown and business devices a consumed prior actually revenue even
many to and physicians on pandemic of companies, we on prescribe Similar also to have supply impact our but navigating the availability of not COVID-XX employee issues. products, the chain only seen
in January orders February, orders compared down XX% down to and are of and average. January approximately the were the average our compared orders and March February number XX% April to
going to order higher numbers orders be year's in QX last XX% forward. doubling and come than still to of the compared to last than We QX numbers year, QX expect more the back in in and same
for the in the for many with force speaks need our relationships This the patients non-opioid prescribers non-addictive prescription has decline strength sales in volumes solutions pain. minor to and prescribe to temporary them orders
therefore in and on uses supplies, less collections. -- and revenue time related revenue reminder, from a As orders and the slowdown short-term cash me, impact revenue recognized patient our an from excuse order an over typically is device the has
to adds and April quarter strong, which collections our year first full cash in in Our this were our the confidence of estimates. year
continue or staying employees difficult suspected during at operations due home period. interruption this despite to illness without either our Our anxiety of few a an
Our and raw supply uninterrupted chain non-Chinese materials. second all components remains our as secured sources of for we previously
placed it's receive immediately months' with critical components as on orders on products in-house several a assembly of a our finished to XX the four months months XX for for have to our prescription. pain to shelf, have ability over hand practice to on addition, In to top materials. us we in and vendors keep of of It internal is the patient of the ship
The use and issue get opioids patients to opioid prescription this to of physicians we're working technology be the a first serious continues pain. strength defense epidemic line to our for increasingly of when off in country as and treating
devastating of to tens the the due impact die opioid level where thousands yearly has Currently, abuse. reached
continue to technology more aware physicians develop tools effects. literally make no We of to has our that side
new of Our some as management pain the puts products our for rehabilitation the incontinence pain best stand in move industry for in and stroke for strong and a for device the out rehabilitation, management, markets. that wave rehabilitation us treatment very in in position makes way still product products
see in of well as for our divisions both above product to management our great as huge a volume continue pain monitor. We area unmet potential potential existing revenue-generating for
The for year. balance blood patient's earlier intended monitor of monitor probably get is most surgical we already this fluid centers. non-invasive managed clearance and and As you hospitals know, CMXXXX to a monitor CMXXXX in to FDA fluid
We fewer safer substantial initially to and of lead bleeding detect less common as unmet needs mortality, believe target internal and and is are hospitals ICU serious and surgeries blood rooms display until rooms recovery product biggest typically complications the We one in loss expect surgeries, complications, difficult today. will today where to well to operating occur. as this that
turn call to over now Dan I CFO. Moorhead, the will